Menu Search
Equities

Pfizer Inc

PFE:NYQ

Pfizer Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.13
  • Today's Change0.19 / 0.76%
  • Shares traded45.05m
  • 1 Year change-17.06%
  • Beta0.6302
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 15-Nov-24
Select bar for recommendation details.
Recommendations15-Nov-24
Buy4
Outperform8
Hold14
Sell0
Strong Sell1

Share price forecast in USD

The 24 analysts offering 12 month price targets for Pfizer Inc have a median target of 32.00, with a high estimate of 45.00 and a low estimate of 25.00. The median estimate represents a 28.31% increase from the last price of 24.94.
High80.4%45.00
Med28.3%32.00
Low0.2%25.00

Dividends in USD

In 2023, Pfizer Inc reported a dividend of 1.64 USD, which represents a 2.50% increase over last year. The 11 analysts covering the company expect dividends of 1.68 USD for the upcoming fiscal year, an increase of 2.62%.
Div growth (TTM)2.50%
More ▼

Earnings history & estimates in USD

On Oct 29, 2024, Pfizer Inc reported 3rd quarter 2024 earnings of 1.06 per share. This result exceeded the 0.62 consensus of the 15 analysts covering the company and outperformed last year's 3rd quarter results by 1.23.
The next earnings announcement is expected on Jan 28, 2025.
Average growth rate+256.61%
Pfizer Inc reported annual 2023 earnings of 1.84 per share on Jan 30, 2024.
Average growth rate+12.80%
More ▼

Revenue history & estimates in USD

Pfizer Inc. had 3rd quarter 2024 revenues of 17.70bn. This bettered the 14.95bn consensus of the 14 analysts covering the company. This was 3.17% below the prior year's 3rd quarter results.
Average growth rate+8.66%
Pfizer Inc. had revenues for the full year 2023 of 58.50bn. This was 41.70% below the prior year's results.
Average growth rate+14.17%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.